Devika Kir, MD
Interventional Cardiology · Davenport, IANPI 1023466414
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,312 of the $10,625 with a category attached, or 68.8%. 20 manufacturers reported payments, led by Edwards Lifesciences at 34.6% of the total. Reporting peaked in 2022 at $3,274 and has fallen 50.7% since, to $1,616 in 2025.
Across 154 payments — averaging $68.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$4K
- Medtronic$2K
- Philips North America LLC$1K
- Inari Medical, Inc.$929
- Abbott$766
- Boston Scientific$495
- plus $2K from 14 others
What the payments were for
- Travel & lodging$3,31231%
- Food & beverage$7,31269%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 38 | $3,673 |
| Medtronic | 51 | $1,511 |
| Philips North America LLC | 5 | $1,141 |
| Inari Medical, Inc. | 15 | $929 |
| Abbott | 11 | $766 |
| Boston Scientific | 10 | $495 |
| Cardiovascular Systems Inc. | 3 | $411 |
| Davol Inc. | 2 | $278 |
| AstraZeneca | 2 | $250 |
| Penumbra, Inc. | 2 | $211 |
| Abiomed | 4 | $204 |
| Impulse Dynamics (USA) Inc. | 1 | $144 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Shockwave Medical, Inc | 3 | $105 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $104 |
| GE HealthCare | 1 | $100 |
| Chiesi USA, Inc. | 1 | $79 |
| Amarin Pharma, Inc. | 1 | $57 |
| Asahi Intecc USA, Inc. | 1 | $23 |
| Johnson & Johnson | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (9520) IGT Devices Undivided$985
- Edwards SAPIEN 3 Transcatheter Heart Valve$768
- FLOWTRIEVER CATHETER, S$744
- PASCAL$603
- EVOQUE$494
- CT THROMBECTOMY SYSTEM KIT$448
- Diamondback Coronary$411
- TurboHawk$303
- WATCHMAN Access System$257
- FARXIGA$250
- ARISTA AH FLEXITIP$148
- AMPLATZER$147
- OPTIMIZER$144
- PHASIX$131
- Indigo System$115
- CardioMEMS HF System$112
- PERCLOSE PROGLIDE$107
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$106
- LifeVest$104
How this compares
$10,625 in reported general payments places this provider in the 70th percentile of 64 interventional cardiology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 80 | $100,330 |
| XareltoRivaroxaban | 28 | $29,432 |
| EntrestoSacubitril/Valsartan | 20 | $22,868 |
| Midodrine Hcl | 15 | $1,521 |
| Metoprolol Succinate | 128 | $1,438 |
| Rosuvastatin Calcium | 70 | $979 |
| Potassium Chloride | 35 | $814 |
| Atorvastatin Calcium | 107 | $772 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 60 | $731 |
| Ezetimibe | 29 | $670 |
| Lisinopril | 97 | $572 |
| Losartan Potassium | 75 | $526 |
| ClopidogrelClopidogrel Bisulfate | 92 | $506 |
| Nitroglycerin | 64 | $499 |
| Furosemide | 101 | $458 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $20 | $29,43228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 64 interventional cardiology providers in Iowa.
Other interventional cardiology in Davenport
- Nicolas ShammasDavenport$808K
- Eric DippelDavenport$100K
- Srikanth KasulaDavenport$43K
- Amit BahiaDavenport$8K
- Parth DesaiDavenport$5K
- Adnan YousafDavenport$4K
- Atul ChawlaDes Moines$78K
- Magdi GhaliWest Des Moines$64K
- David McAllisterDes Moines$55K
- Daniel ShivapourDes Moines$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.